CClinicalTrials.gg
CompletedNCT03539289MADIETUpdated Jul 16, 2020

Evaluate the Effect of Diet on Gastrointestinal Adverse Events in Patients With IPF Treated With Pirfenidone

An interventional study of MUFA Diet and SFA Diet in Pulmonary Disease, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Completed at 6 sites in 6 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-07-16.

Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2017, registered May 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
40 Years and older
Sex
All
01

Study summary

The primary objective is to compare the incidence of gastrointestinal AEs in patients treated with IPF, initiating pirfenidone for the first time, according to the type of diet (MUFA vs SFA). Gastrointestinal AEs rates between study groups will be evaluated during the first 16 weeks of pirfenidone treatment.

Read the detailed description

IPF is a chronic, progressive, irreversible disease that ends in respiratory failure and death. The average survival time is 2-5 years from the onset of the first symptoms. IPF patients are often treated with pirfenidone, and the response is positive, however there are gastrointestinal side effects. The data published about patient adherence to pirfenidone treatment relates to the emergence of gastrointestinal AEs, which is variable and appears to have a lower incidence in the hospitals in the south of Europe, who report fewer serious gastrointestinal AEs than in countries from the north of Europe.

Recent data from the Spanish Registry have reported a prevalence of 6,3% of GI effects with pirfenidone in 270 IPF patients under treatment (IPF-Spanish Registry June 2016), while in Netherlands and Belgium the reported GI effects are around 36%, and associated with treatment discontinuation in 7,9% of patients.

Even though the ingestion of food during the taking of medication and other measures recommended for the prevention of symptoms may have a beneficial effect with respect to gastrointestinal AEs, up to now there have been no studies about the influence of diet on these events. Therefore, it is possible that the differences in the patients' habitual diet, i.e. the composition in quantity and types of fat ingested, may be the source of the variability of the gastrointestinal AEs observed between countries.

Distinct dietary models have been taking shape over the past decades. In countries such as England, central and northern Europe, and a large part of North America, dietary habits characterized by a high consumption of saturated and hydrogenated fats in the form of pastries and pre-cooked products, veal, pork, and lamb (>150 g per day), butter and milk fats, and scant consumption of fruits, greens, vegetables, and whole-grain cereals. It is called the Occidental Diet (OD). Various studies have associated it, as an environmental factor, with diseases such as vascular accidents, diabetes, metabolic syndrome, and various types of cancer.

On the other hand, traditional Mediterranean diets have been associated with low rates of chronic diseases and high life expectancy among the populations that consume them. They are characterized by an abundance of greens, garden produce, fresh fruit, legumes and cereals; a variable quantity, according to the zone, of olive oil, which is the main cooking fat; a moderate consumption of alcohol, mainly in the form of wine; some fish; moderate ingestion of dairy foods, and low consumption of meat.

The main characteristic of the Mediterranean diet is that the ratio of monounsaturated fatty acids (MUFA) to saturated fatty acids (SFA) is much higher than in other zones of Europe and North America due to a high consumption of olive oil as the main cooking oil. Olive oil fills distinct functions in the gastrointestinal tract. Being the fat that provides the best digestibility and whose mechanism of action is based on an inhibition of gastric motility, thus promoting a lower degree of gastroesophageal reflux. That is the reason that it is used extensively among Nutrition professionals when patients present low oral tolerance(22-24). Olive oil, also, has been used to mitigate postoperative nausea and vomiting.

This study will analyze the AEs in IPF patients in 6 countries, who are prescribed pirfenidone. They will be divided into SFA and MUFA arms and the AEs of each arm statistically analyzed.

02

Conditions studied

  • Pulmonary Disease

Browse trials for

Keywords

  • IPF
  • Mitigating Adverse Events
03

In context

Lung Diseases

3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.

This study's enrollment of 90 is above the median of 72 across 2,118 interventional studies indexed under Lung Diseases.

Browse Lung Diseases studies →

Lead sponsor

Consorcio Centro de Investigación Biomédica en Red (CIBER) is the lead sponsor of 18 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Signed Informed Consent Form
  • Ability to comply with the study protocol in the opinion of the Investigator
  • Age > 40 years
  • Naiive-treated patients with diagnosis of IPF at least 1 week but not more than 5 years prior to study baseline
  • Confirmation of IPF diagnosis by the Investigator of each Centre, in accordance with the 2011 international consensus guidelines (Raghu et al. 2011), at baseline
  • IPF that meet criteria for pirfenidone treatment initiation according to local reimbursement policy
  • Approval of potential study participation by Central Committee (FFQ shows a clear diet predominance).

Defined and regular diet for at least six months prior to baseline (i.e. no frequent changes in the type of diet).

  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a non-hormonal contraceptive method with a failure rate of \<1% per year during the Treatment Period and for at least 28 days after the last dose of study treatment
  • For men who are not surgically sterile: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

    • History of coexistent and clinically significant (in the opinion of the Investigator) chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma, inadequately treated sleep-disordered breathing, or any clinically significant pulmonary diseases or disorders other than IPF

      • History of any connective tissue disease, including, but not limited to: rheumatoid arthritis, scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, or mixed connective tissue disease
      • History of clinically significant environmental exposure to agents known to cause pulmonary fibrosis, including asbestos, beryllium, silica, and other occupational dusts; amiodarone, nitrofurantoin, and other drugs; radiation; and birds, feathers, molds, and other inhaled antigens known to cause hypersensitivity pneumonitis
      • Participation in any other investigational trial throughout the study
      • Any serious medical condition that, in the opinion of the Investigator, may pose an additional risk in administering study treatment to the patient
      • Expecting a lung transplant in \<12 months
      • Certain laboratory abnormalities or findings at baseline, including:

        • Total bilirubin > 5 the upper limit of normal (ULN)
        • AST/SGOT or ALT/SGPT >1.5 ULN
        • Alkaline phosphatase >2.0 ULN
        • Creatinine clearance \<40 mL/min, calculated using the Cockcroft-Gault formula
      • Pregnant or lactating, or intending to become pregnant during the study
      • Pharmacological treatments (concomitant-therapy) at baseline that may cause patient gastrointestinal side effects
      • Major gastro-intestinal disorders at baseline (gastric or bowel surgery, ulcus). Patients with gastroesophagic reflux or other minor digestive disorders can be included.
      • Pregnant patients, or women of child-bearing potential, not using a reliable non-hormonal? contraceptive method
      • Planning to change the type of diet in the next 4 months
      • Not able to follow a specific type of diet or cannot be allocated to a specific type of diet (MUFA vs SFA) by the Central Committee
      • Previous use, intolerance, or allergy to pirfenidone or hypersensitivity to the active substance or to any of the excipients
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Other
    MUFA Diet

    Monounsaturated Fatty Acids Diet

    Behavioral: MUFA Diet

  • Other
    SFA Diet

    Saturated Fatty Acids Diet

    Behavioral: SFA Diet

Interventions

  • BehavioralMUFA Diet

    Control of patient MUFA Diet

  • BehavioralSFA Diet

    Control of patient SFA Diet

06

What researchers measure

Primary outcomes

  1. Incidence of gastrointestinal AEs

    • To compare the incidence of gastrointestinal AEs in patients with IPF initiating pirfenidone for the first time - according to the type of diet (Monounsaturated Fatty Acids \[MUFA\] vs Saturated Fatty Acids \[SFA\]). Gastrointestinal AEs rates between study groups will be evaluated during the first 16 weeks of pirfenidone treatment

    Time frame: First 16 weeks of pirfenidone treatment

07

Study locations

6 sites
  • University Hospital Essen
    Essen, 45239, Germany
  • University of Crete, Eraklion
    Heraklion, 741 00, Greece
  • Università de Catania
    Catania, Sicily 95123, Italy
  • Erasmus MC, Rotterdam
    Rotterdam, 3015, Netherlands
  • Hospital Universitario de Bellvitge
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Brompton Hospital
    London, SW3 6NP, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03539289
Lead sponsor
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Collaborators
Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge
Responsible party
Sponsor
First posted
May 29, 2018
Start date
Dec 28, 2017
Primary completion
Apr 22, 2020
Completion
Apr 22, 2020
Last update
Jul 16, 2020

Study contacts

María Molina Molina
principal investigator · Unidad Funcional de Intersticio Pulmonar (UFIP).Servicio de Neumología. Hospital Universitario de Bellvitge

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion